FLT3 and acute myeloid leukemia: This is embodied in the very latest published recommendations, 2022 European LeukemiaNet risk classification by genetics at initial diagnosis in AML, which categorizes NPM1mut/FLT3‐ITD as intermediate‐risk irrespective of FLT3‐ITD AR.31